Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 3

2(40.0%)

N/A

1(20.0%)

5Total

Phase 2(2)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07398560Phase 2Not Yet Recruiting

Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study

Role: lead

NCT06856616Active Not Recruiting

Predicting Long-Term Clinical Outcomes in Chinese Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Role: lead

NCT05360420Not ApplicableUnknown

Diagnosis of Nodules ≤2 cm Based on US and CEUS Compared With Current Clinical Procedure

Role: collaborator

NCT03815474Phase 2Unknown

Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients

Role: collaborator

NCT03286920Unknown

Effect of Postoperative Family Nutrition Mode on Weight/BMI of Patients With Esophageal Cancer

Role: collaborator

NCT02630108Phase 3Unknown

TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma

Role: collaborator

NCT01245959Phase 3Unknown

Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

All 7 trials loaded